Phase I/II study of cetuximab in combination with cisplatin or carboplatin and fluorouracil in patients with recurrent or metastatic squamous cell carcinoma of the head and neck.
about
Association of cetuximab with adverse pulmonary events in cancer patients: a comprehensive reviewEGFR Targeting in Hormone-Refractory Prostate Cancer: Current Appraisal and Prospects for Treatment.Cetuximab therapy for head and neck squamous cell carcinoma: a systematic review of the data.Recent results of cetuximab use in the treatment of squamous cell carcinoma of the head and neck.Quality of life of patients receiving platinum-based chemotherapy plus cetuximab first line for recurrent and/or metastatic squamous cell carcinoma of the head and neck.Curcumin: A review of anti-cancer properties and therapeutic activity in head and neck squamous cell carcinoma.Phase II selection design trial of concurrent chemotherapy and cetuximab versus chemotherapy followed by cetuximab in advanced-stage non-small-cell lung cancer: Southwest Oncology Group study S0342EGFR targeting drugs in the treatment of head and neck squamous cell carcinoma.The contribution of cetuximab in the treatment of recurrent and/or metastatic head and neck cancerRash rates with egfr inhibitors: meta-analysis.Cytotoxic effect of lapatinib is restricted to human papillomavirus-positive head and neck squamous cell carcinoma cell lines.Cetuximab plus platinum-based chemotherapy in head and neck squamous cell carcinoma: a randomized, double-blind safety study comparing cetuximab produced from two manufacturing processes using the EXTREME study regimenAntiepidermal growth factor receptor therapy in squamous cell carcinoma of the head and neck.Synergistic antitumor effects of liposomal honokiol combined with cisplatin in colon cancer models.Time-dependent pretreatment with bevacuzimab increases tumor specific uptake of cetuximab in preclinical oral cavity cancer studies.Loss of epidermal growth factor receptor expression in oral squamous cell carcinoma is associated with invasiveness and epithelial-mesenchymal transition.Pharmacokinetic drug-drug interaction potentials for therapeutic monoclonal antibodies: reality check.Tyrosine kinase inhibitors in pediatric malignancies.Recent advances relating to the clinical application of naked monoclonal antibodies in solid tumorsRecurrent head and neck cancer: current treatment and future prospects.Review of cetuximab in the treatment of squamous cell carcinoma of the head and neckEvolving therapies in the treatment of hepatocellular carcinomaThe role of cetuximab for the treatment of squamous cell carcinoma of the head and neck.Cisplatin-Based Chemotherapy Options for Recurrent and/or Metastatic Squamous Cell Cancer of the Head and Neck.Overview of current and future biologically based targeted therapies in head and neck squamous cell carcinoma.Eribulin sensitizes oral squamous cell carcinoma cells to cetuximab via induction of mesenchymal-to-epithelial transition.Treatment of head and neck cancers: issues for clinical pharmacists.Optimal treatment for recurrent/metastatic head and neck cancer.Recent advances in anti-angiogenic therapy of cancerCetuximab in the treatment of squamous cell carcinoma of the head and neck.Cutting edge in medical management of cutaneous oncology.Review of high-risk features of cutaneous squamous cell carcinoma and discrepancies between the American Joint Committee on Cancer and NCCN Clinical Practice Guidelines In Oncology.Interactions Between Therapeutic Proteins and Small Molecules: The Shared Role of Perpetrators and Victims.Immunotherapy for the treatment of colorectal tumors: focus on approved and in-clinical-trial monoclonal antibodies.IL-2- or IL-15-activated NK cells enhance Cetuximab-mediated activity against triple-negative breast cancer in xenografts and in breast cancer patients.New strategies in head and neck cancer: understanding resistance to epidermal growth factor receptor inhibitors.The use of epidermal growth factor receptor monoclonal antibodies in squamous cell carcinoma of the head and neckThe role of EGFR-targeting strategies in the treatment of head and neck cancerTreatment of gastrointestinal neuroendocrine tumors with inhibitors of growth factor receptors and their signaling pathways: recent advances and future perspectives.Growth factor receptors and related signalling pathways as targets for novel treatment strategies of hepatocellular cancer.
P2860
Q21198850-AF84141F-D69F-4494-A6DF-5E0B69C977B5Q33677975-86AAD24C-316B-43F4-A5C5-62AC145D8F50Q33873118-2E0D4E73-C0F4-4DA0-A79F-91CEA388B91BQ33916035-BCE37D13-EA44-4EA6-9412-EB9DE3DE5B93Q34160545-41C4BB5F-7314-4F28-8045-3529A9997819Q34163076-E86D2A49-0D81-4A3C-A8A1-E0A5F1F15D82Q34488787-AF1B2C7A-EC8F-4E30-B13B-363F58C52F00Q34618994-93234612-8D13-454C-88A1-962BF5DDB783Q34622547-FA058AE2-64E6-43B0-8745-6316E19F2A30Q34761646-5E005B6D-FA4C-4758-8D42-6B3058354FC8Q35067562-8E043C95-93A6-4AC6-8939-07A4D15B140DQ35894552-1577840D-D4FC-45E3-BBEB-C29CC76624F2Q36072292-7321316A-CDDB-4AA7-907E-0C6F9E27575BQ36126660-BAC332B9-5138-4C8A-AE74-773E7DA3F820Q36216452-30413A1A-334C-4C0A-AC58-B9DDA206A687Q36503161-46060394-703B-491E-9604-47FE964ED7F1Q36927353-ADB91B9A-B30A-4EDF-98C5-314ABF0D5C56Q36977823-A78EFDCB-67C6-434D-BFAB-ABEBA046E49DQ37055023-FCD992D6-573D-48DF-AE57-80B5C7523D85Q37118936-FE45FC32-834D-4A29-8D0C-18F49FDAF16BQ37160382-363084A4-39E0-47F1-B07E-19DB1D098573Q37290714-8FFE5A24-C236-4F88-A06A-FED839B83B70Q37322050-B3E8BB63-C686-4768-AF0B-AF969868CC7DQ37328494-79738E8F-AA03-49F0-A853-7B91F79A0DABQ37414399-974B5787-1C2E-4C83-AEAC-B0E3AF328263Q37419295-1874B698-B3FD-4BE6-AF43-E6020C749567Q37461437-99F19F46-C3E1-40A1-8147-CF235821F321Q37799934-9871C2F0-24B1-4B86-827D-70170DD3772FQ37852512-95EE913E-E236-48C9-A2D8-FD763421BF30Q37866779-5B398E09-450E-4A7D-B7C5-FE2F08CA3449Q38013803-55AFAF9C-335F-4E7C-949E-6806B31172C9Q39018620-2095B5CC-CE3D-4720-823B-C4D726DA3C0AQ39047005-47A7AF42-562D-4E1C-964E-5E471EE49980Q39110385-168E7F85-7134-407F-8DB4-2CDF7A97C435Q39259470-8CC7E673-425E-4FBE-9942-FBB0656183AEQ41127315-1C0B7281-B247-4A85-8BE3-CA0975264D60Q41513098-68804B0A-6704-4748-BC8C-83E1C9CEB21BQ41869362-74D4DEDC-7042-4E3F-8BAC-9604090DC334Q43097453-68B4701C-4597-49AF-805C-53BC5AE8824FQ43141124-D63981D0-9E9B-4797-A7C8-C931B7708349
P2860
Phase I/II study of cetuximab in combination with cisplatin or carboplatin and fluorouracil in patients with recurrent or metastatic squamous cell carcinoma of the head and neck.
description
2006 nî lūn-bûn
@nan
2006 թուականի Մայիսին հրատարակուած գիտական յօդուած
@hyw
2006 թվականի մայիսին հրատարակված գիտական հոդված
@hy
2006年の論文
@ja
2006年論文
@yue
2006年論文
@zh-hant
2006年論文
@zh-hk
2006年論文
@zh-mo
2006年論文
@zh-tw
2006年论文
@wuu
name
Phase I/II study of cetuximab ...... arcinoma of the head and neck.
@ast
Phase I/II study of cetuximab ...... arcinoma of the head and neck.
@en
type
label
Phase I/II study of cetuximab ...... arcinoma of the head and neck.
@ast
Phase I/II study of cetuximab ...... arcinoma of the head and neck.
@en
prefLabel
Phase I/II study of cetuximab ...... arcinoma of the head and neck.
@ast
Phase I/II study of cetuximab ...... arcinoma of the head and neck.
@en
P2093
P356
P1476
Phase I/II study of cetuximab ...... arcinoma of the head and neck.
@en
P2093
Ahmad Awada
Andreas Harstrick
Antonio Lopez-Pousa
Armin Schueler
Dominique Rosine
Fernando Rivera
Jean Bourhis
Lionel Duck
Lionel Geoffrois
M Eugenia Vega Villegas
P304
P356
10.1200/JCO.2005.04.3547
P407
P577
2006-05-22T00:00:00Z